LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse (Q30491802)

20 August 2017

LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse (English)

1 reference

20 August 2017

1 reference

14

Stephen J Gardell

1 reference

20 August 2017

Elaine M Quinet

1

1 reference

20 August 2017

Michael D Basso

2

1 reference

20 August 2017

Anita R Halpern

3

1 reference

20 August 2017

David W Yates

4

1 reference

20 August 2017

Robert J Steffan

5

1 reference

20 August 2017

Valerie Clerin

6

1 reference

20 August 2017

Christine Resmini

7

1 reference

20 August 2017

James C Keith

8

1 reference

20 August 2017

Thomas J Berrodin

9

1 reference

20 August 2017

Irene Feingold

10

1 reference

20 August 2017

Wenyan Zhong

11

1 reference

20 August 2017

Helen B Hartman

12

1 reference

20 August 2017

Mark J Evans

13

1 reference

20 August 2017

Elizabeth DiBlasio-Smith

15

1 reference

20 August 2017

William M Mounts

16

1 reference

20 August 2017

Edward R LaVallie

17

1 reference

20 August 2017

Jay Wrobel

18

1 reference

20 August 2017

Ponnal Nambi

19

1 reference

20 August 2017

George P Vlasuk

20

1 reference

20 August 2017

24 March 2009

1 reference

Journal of Lipid Research

20 August 2017

1 reference

20 August 2017

50

1 reference

20 August 2017

12

1 reference

20 August 2017

2358-2370

1 reference

Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Liver X receptors (LXR) as therapeutic targets in dyslipidemia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Recent advances in liver X receptor biology and chemistry

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Mouse models for atherosclerosis and pharmaceutical modifiers.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists for the treatment of atherosclerosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Intestinal ABCA1 directly contributes to HDL biogenesis in vivo

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Regulation of complement C3 expression by the bile acid receptor FXR.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

LXRs: new therapeutic targets in atherosclerosis?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Identification of macrophage liver X receptors as inhibitors of atherosclerosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Role of LXRs in control of lipogenesis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Identification of a chemical tool for the orphan nuclear receptor FXR.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

The liver X receptor and atherosclerosis

20 June 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M900037-JLR200

T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M900037-JLR200

LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M900037-JLR200

Carboxylic acid based quinolines as liver X receptor modulators that have LXRbeta receptor binding selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M900037-JLR200

Synthetic LXR agonists increase LDL in CETP species

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M900037-JLR200

Novel progesterone receptor modulators with gene selective and context-dependent partial agonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M900037-JLR200

Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M900037-JLR200

Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M900037-JLR200

Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M900037-JLR200

Transgenic Mice Expressing Human Fibroblast Growth Factor-19 Display Increased Metabolic Rate and Decreased Adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M900037-JLR200

Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781308

10.1194/JLR.M900037-JLR200

26 November 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

19318684

1 reference